Results 71 to 80 of about 27,341 (230)

Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial.

Circulation, 2019
BACKGROUND Evidence regarding the primary prevention of coronary artery disease (CAD) events by LDL-C-lowering therapy in older individuals aged ≥75 years is insufficient.
Y. Ouchi, J. Sasaki, H. Arai, K. Yokote, K. Harada, Y. Katayama, T. Urabe, Yasufumi Uchida, M. Hayashi, N. Yokota, H. Nishida, Takatoshi Otonari, T. Arai, I. Sakuma, Kazuo Sakabe, M. Yamamoto, Takashi Kobayashi, S. Oikawa, S. Yamashita, H. Rakugi, T. Imai, Shiro Tanaka, Y. Ohashi, M. Kuwabara, Hideki Ito   +24 more
semanticscholar   +1 more source

Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease

, 2010
Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy.
Robert Guthrie
core   +1 more source

Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis

European Respiratory Journal
Extract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal interstitial lung disease characterised by excessive extracellular matrix deposition and structural distortion with fibrosis [1, 2].
Chanho Lee, S. Kwak, Jisu Han, Ju Hye Shin, B. Yoo, Y. Lee, J. Park, Beom Jin Lim, Jin Gu Lee, Young Sam Kim, S. Kim, Soo Han Bae   +11 more
semanticscholar   +1 more source

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.

Atherosclerosis, 2018
BACKGROUND AND AIMS Patients with hyperlipidemia who are unable to tolerate optimal statin therapy are at increased cardiovascular risk due to ongoing elevations in low-density lipoprotein cholesterol (LDL-C).
C. Ballantyne, M. Banach, G. Mancini, N. Lepor, J. Hanselman, Xin Zhao, Lawrence A Leiter   +6 more
semanticscholar   +1 more source

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in ...
Viveca Ritsinger, Magnus Sundbom, Jonatan Dereke, Åsa Ericsson, Thomas Cars, Maria K. Svensson, Anna Norhammar   +6 more
wiley   +1 more source

30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (2014)

, 2014
Background: Ezetimibe reduces absorption of dietary and biliary cholesterol by inhibiting its transport across the intestinal wall. Ezetimibe receives public subsidy in Australia from the Pharmaceutical Benefits Scheme (PBS) for very restricted ...
Susan, Tett, Martin, Jennifer, Michael, David, Ostini, Remo, Hollingworth, Samantha A.   +4 more
core   +1 more source

Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials

Atherosclerosis
Background and aims Statins, ezetimibe and statins-ezetimibe combination therapy are recommended lipid-lowering therapies (LLTs) in children with heterozygous familial hypercholesterolaemia (HeFH).
A. Llewellyn, Mark Simmonds, David Marshall, Melissa Harden, B. Woods, S. Humphries, U. Ramaswami, L. Priestley-Barnham, M. Fisher, L. Tata, N. Qureshi   +10 more
semanticscholar   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Synthesis and Modeling of Ezetimibe Analogues

, 2021
Ezetimibe is a well-known drug that lowers blood cholesterol levels by reducing its absorption in the small intestine when joining to Niemann-Pick C1-like protein (NPC1L1).
David Díez, Alejandro Manchado, Mateo M. Salgado, Carlos T. Nieto, Narciso M. Garrido   +4 more
core   +1 more source